Franklin Biolabs CEO Selected as a 2026 Women of Influence by the Philadelphia Business Journal
Learn more

Long-term biodistribution and shedding analysis for lentiviral-based CAR-T therapies

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Long-term biodistribution and shedding analysis for lentiviral-based CAR-T therapies

Long-Term Biodistribution and Shedding Studies for Lentiviral CAR-T Therapies

CELL & GENE | RNA | BIOLOGICS

  • Quantifying Persistence and Safety for IND-Enabling Packages.*

Long-term biodistribution and shedding studies are required components of the preclinical safety program for cell therapies utilizing integrating lentiviral vectors, such as CAR-T. These studies quantify the persistence, distribution, and clearance of genetically modified cells and assess the potential for vector shedding into the environment. Using highly sensitive qPCR and ddPCR methods, our GxP-compliant laboratories analyze a comprehensive set of tissues and excreta to generate the robust data package necessary to support Investigational New Drug (IND) applications and ensure patient safety.

    What is the primary goal of a CAR-T biodistribution study?

    A: To determine the location, quantity, and persistence of the administered CAR-T cells in both target and non-target tissues over time. This informs the therapy’s safety profile.

    Why is shedding analysis required for lentiviral vectors?

    A: Shedding studies assess the risk of viral particles or genetically modified cells being released from the patient through excreta (e.g., urine, feces, saliva), which is a regulatory requirement to evaluate potential environmental and transmission risks.

    What is the typical duration for these long-term studies?

    A: Study duration is dictated by cell persistence. It often extends from three months to over a year post-infusion to capture the full distribution and clearance kinetics, aligning with regulatory expectations for long-term safety monitoring.

    Which tissues are required for analysis?

    A: A standard panel includes blood, bone marrow, lymphoid tissues (spleen, lymph nodes), major organs (liver, lung, kidney, heart, brain), reproductive tissues (gonads), and the site of administration to assess non-target tissue biodistribution.

Defining the In Vivo Fate of Lentiviral-Modified Cells

For cell therapies engineered with integrating lentivviral vectors, regulatory agencies require a comprehensive understanding of the in vivo fate of the modified cells. Biodistribution studies are designed to track the migration and persistence of CAR-T cells following infusion. This analysis provides direct evidence of cellular trafficking to target tissues, such as tumors or lymphoid organs, and evaluates their presence in off-target sites.

The data generated are fundamental to the overall safety assessment. They help characterize potential risks associated with:

  • Insertional Oncogenesis: Long-term persistence in non-target tissues requires evaluation.

  • Germline Transmission: Analysis of gonadal tissues is performed to rule out the potential for vector integration into reproductive cells.

  • Immunogenicity: Unexpected distribution patterns can inform investigations into host immune responses.

A close-up of a gloved hand handling PCR tubes with blue liquid in a laboratory rack, with a blue color overlay.

A close-up of a Pall Corporation single-use bioreactor system in a cleanroom environment, showing the control panel, vessel with cell culture media, and tubing.

Quantitative Bioanalysis for Vector Copy Number

The core of any biodistribution or shedding study is the precise quantification of vector sequences in biological samples. Our laboratories employ validated quantitative PCR (qPCR) and droplet digital PCR (ddPCR) assays to measure vector copy number (VCN) relative to the amount of host genomic DNA. This highly sensitive approach allows for the detection of very low levels of modified cells across a wide range of sample types.

We develop and validate product-specific assays to ensure accuracy and compliance with GxP standards. The comprehensive analysis includes:

  • Whole blood and isolated peripheral blood mononuclear cells (PBMCs)

  • A full panel of tissues collected at scheduled and terminal endpoints

  • Excreta and body fluids (urine, feces, saliva) for shedding assessment

Strategic Precedent for Long-Term Vector Safety

The regulatory expectation for robust, long-term persistence data is well-established for therapies involving viral vectors. For example, foundational studies in the gene therapy field have demonstrated the importance of long-term monitoring to confirm durable efficacy and a stable safety profile (PMID: 33609733). While the modality differs, the principle is directly applicable: demonstrating control over the vector’s long-term biological activity is a key component of de-risking a program for clinical advancement. Our study designs incorporate these strategic precedents to meet and exceed regulatory expectations.

At our >100,000 sq ft facility, we guide sponsors through the typical 18-24 month IND timeline, leveraging our deep experience in preclinical program design. Our rigorous approach has supported a 100% IND success rate for our clients since 2019, with the Franklin Biolabs brand itself having launched in 2024. This record is built on designing studies that generate the robust, submission-ready data packages required for clinical advancement.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities